Notice of Annual General Meeting and Explanatory Memorandum

​​Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Thursday 28th December 2017 at 4.00 p.m. (Central Standard Time) and Friday 29th December 2017 at 9.00 a.m. (Australian Eastern Standard Time).

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM

Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:

28th December 2017 at 4.00 p.m. (Central Standard Time) and 29th December 2017 at 9.00 a.m. (Australian Eastern Standard Time)

Meeting to be held by teleconference (Dial-in details below):

  • United States - 1 800 444 2801
  • Australia - 1 800 422 547 / 02 9037 8402
  • New Zealand - 0 800 440 176
  • Switzerland - 0800 564 606
  • Netherlands - 8000 220 915
  • United Kingdom - 0 800 234 6984
  • Hong Kong - 800 903 191

Participant Code: 5687312

For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click: 

https://www.newswire.com/files/f6/ca/0065e1b906b41b8f652b12941954.pdf

_________________________________

21 November 2017

Dear Shareholder,

On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at a General Meeting of shareholders (GM), which has been scheduled as follows:

Date: 28th December 2017 (CST), 29th December 2017 (AEST)

Time: 4.00 p.m. (CST), 9.00 a.m. (AEST)

Venue: Held by telephone conference (dial-in details above) or by physical attendance at Unit 4, 476 Gardeners Road, Alexandria New South Wales 2015, Australia

Outline of the items of business

At this GM, we will provide an opportunity for shareholders to consider the following item of business:

  • Removal of Robert Joseph as director of the Company.

Details of this item are contained in the enclosed Notice of GM and Explanatory Memorandum.

Voting at the meeting or by proxy

A proxy form accompanies the enclosed Notice of Meeting. If you wish to attend the GM in person, please bring a copy of the proxy form with you. Registration will be available from 8.45 a.m. (AEST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of Meeting on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.

On behalf of all of the Directors, we look forward to hearing from you at the GM.

Yours sincerely,

Alan Bell
Chairman

For more information on the Meeting, please contact the Company's Chief Financial Officer, Brad McCarthy, by telephone on +61 2 8338 2832 or, by email at brad.mccarthy@parnell.com.

Source: Parnell Pharmaceuticals Holdings Ltd

Share:


Categories: Business News, Pharmaceuticals and Biotech, Business

Tags: animal health solutions, animal pharma, Parnell, Parnell Pharmaceuticals


About Parnell

View Website

Parnell (OTC:PARNF) is a fully integrated, veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions.